Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Syntrix Completes Initial SX-682 Dosing in Cancer Trial Campaign

americanpharmaceuticalreviewNovember 05, 2020

Tag: Syntrix Pharmaceuticals , SX-682 , cancer

PharmaSources Customer Service